# Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

> **NCT01261325** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 768 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Placebo
- **DRUG:** Brivaracetam
- **DRUG:** Brivaracetam
- **DRUG:** Antiepileptic drugs with market authorization available per country

## Key facts

- **NCT ID:** NCT01261325
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 768 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01261325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01261325, "Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01261325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*